Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Boule Diagnostics AB's Average Total Inventories for the quarter that ended in Jun. 2026 was kr64.9 Mil. Boule Diagnostics AB's Revenue for the
three
months ended in Jun. 2026 was kr112.2 Mil.
Boule Diagnostics AB's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.58.
Boule Diagnostics AB's Inventory-to-Revenue for the quarter that ended in Jun. 2026
declined
from Mar. 2026 (0.60) to Mar. 2026 (0.58)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Boule Diagnostics AB's Days Inventory for the
three
months ended in Jun. 2026 was 89.25.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Boule Diagnostics AB's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.02.
Boule Diagnostics AB (CHIX:BOULs) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Boule Diagnostics AB's Days Inventory for the
three
months ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB Inventory-to-Revenue Related Terms
Boule Diagnostics AB Inventory-to-Revenue Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: Inventory-to-Revenue Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Inventory-to-Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Inventory-to-Revenue falls into.
Boule Diagnostics AB Inventory-to-Revenue Calculation
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Boule Diagnostics AB's Inventory-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (CHIX:BOULS) has a Inventory-to-Revenue of 0.58 as of Jun. 2026. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Boule Diagnostics AB and its competitors.
Is Boule Diagnostics AB's Inventory-to-Revenue too high?
Boule Diagnostics AB's current Inventory-to-Revenue is 0.58. Overall, Boule Diagnostics AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Inventory-to-Revenue compare to ABT and SYK?
Boule Diagnostics AB's Inventory-to-Revenue of 0.58 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory-to-Revenue for a Medical Devices & Instruments company?
A good Inventory-to-Revenue depends on the Medical Devices & Instruments industry context. However, Inventory-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory-to-Revenue mean?
A high Inventory-to-Revenue can signal that a stock is expensive relative to its fundamentals. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current Inventory-to-Revenue is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Inventory-to-Revenue of 0.58. The stock's GF Value™ is kr55.02, compared to a current price of kr26.30 — trading 52.2% below its estimated fair value. The current Inventory-to-Revenue is 0.58. Boule Diagnostics AB's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory-to-Revenue calculated?
Inventory-to-Revenue is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Inventory-to-Revenue is 0.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 52.2% below its estimated GF Value™ of kr55.02.
Key valuation signals for CHIX:BOULS:
Inventory-to-Revenue: 0.58
GF Value™: kr55.02 vs. price of kr26.30 (52.2% below fair value)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
40GF Score
Get the complete analysis for CHIX:BOULS
Inventory-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
